您的位置:山东大学 -> 科技期刊社 -> 《山东大学学报(医学版)》

山东大学学报(医学版) ›› 2016, Vol. 54 ›› Issue (3): 77-80.doi: 10.6040/j.issn.1671-7554.0.2015.929

• • 上一篇    下一篇

mir-99a的表达与上皮性卵巢癌患者预后的关系

徐志宏1,吴小华2,姚铁柱3,王晓翔1,段晓阳1,史健1   

  1. 1.河北医科大学第四医院肿瘤内科, 河北 石家庄 050011;2.白求恩国际和平医院妇产科, 河北 石家庄050000;3.河北医科大学第四医院心内科, 河北 石家庄 050011
  • 收稿日期:2015-09-28 出版日期:2016-03-10 发布日期:2016-03-10
  • 通讯作者: 姚铁柱. E-mail:13733315579@163.com E-mail:13733315579@163.com

Relationship between mir-99a expression and prognosis of epithelial ovarian cancer

XU Zhihong1, WU Xiaohua2, YAO Tiezhu3, WANG Xiaoxiang1, DUAN Xiaoyang1, SHI Jian1   

  1. 1. Department of Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China;
    2. Department of Obstetrics and Gynaecology, Bethune International Peace Hospital, Shijiazhuang 050000, Hebei, China;
    3. Department of Cardiology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China
  • Received:2015-09-28 Online:2016-03-10 Published:2016-03-10

摘要: 目的 探讨mir-99a在上皮性卵巢癌(EOC)患者中的表达与临床病理特征及预后的关系。 方法 采用实时荧光定量PCR(qRT-PCR)法检测137例EOC患者组织中mir-99a的表达水平,分析mir-99a表达与卵巢癌患者的临床病理资料的相关性。采用Kaplan-Meier法进行生存分析并绘制生存曲线,生存因素采用log-rank检验。 结果 EOC患者组织中mir-99a的表达较癌旁正常组织降低(P<0.001)。mir-99a的低表达与高组织学分级(P=0.027)、淋巴结转移(P=0.001)、腹膜转移(P<0.001)和较高的FIGO分期(P<0.001)有关。Kaplan-Meier分析与log-rank检验结果显示,mir-99a的低表达与EOC患者生存期短有关(对数秩检验,P=0.005)。多因素分析结果显示,mir-99a表达是患者总体生存的独立预测因子(HR为2.368,95%CI:1.621,10.925, P=0.016)。 结论 mir-99a的表达是上皮性卵巢癌患者独立的预后因素,mir-99a可能成为临床实践中一项新的诊断和预后标志物。

关键词: mir-99a, 上皮性卵巢癌, 预后, 临床病理学

Abstract: Objective To investigate the mir-99a expression in epithelial ovarian cancer(EOC), and its relationship with the clinicopathological features and prognosis. Methods The mir-99a expression in 137 cases of EOC tissues was detected with qRT-PCR assay. The correlation between mir-99a expression and clinicopathological features of EOC were analyzed. Survival curves for patients with different mir-99a expressions were plotted using the Kaplan-Meier method and compared using the log-rank test. Results The mir-99a expression reduced significantly in EOC tissues compared with that in adjacent normal tissues(P<0.001). Low mir-99a expression was significantly correlated with higher histological grade(P=0.027), lymph node metastasis(P=0.001), peritoneal metastasis(P<0.001), and higher FIGO stage(P<0.001). Kaplan-Meier analysis with log-rank test revealed that low mir-99a expression was correlated with short survival time of patients with EOC(log-rank test, P=0.005). Multivariate analysis showed that mir-99a expression was an independent prognostic factor for the overall survival(HR: 2.368, 95%CI: 1.621-10.925, P=0.016). Conclusion The mir-99a expression is an independent prognostic factor of patients with EOC. It can serve as a diagnostic and prognostic marker in clinical practice.

Key words: Epithelial ovarian cancer, Prognosis, mir-99a, Clinical pathology

中图分类号: 

  • R737.31
[1] Karimi-Zarchi M, Mortazavizadeh SM, Bashardust N, et al. The clinicopathologic characteristics and 5-year survival rate of epithelial ovarian cancer in Yazd, Iran[J]. Electron Physician, 2015, 7(6): 1399-1406. doi: 10.14661/1399. eCollection 2015.
[2] Cheng W, Liu J, Yoshida H, et al. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract[J]. Nature medicine, 2005, 11(5): 531-537.
[3] Saad AF, Hu W, Sood AK. Microenvironment and pathogenesis of epithelial ovarian cancer[J]. Hormones Cancer, 2010, 1(6): 277-290.
[4] Jönsson JM, Skovbjerg Arildsen N, Malander S, et al. Sex steroid hormone receptor expression affects ovarian cancer survival[J]. Transl Oncol, 2015, 8(5): 424-433.
[5] Jiang H, Qu L, Wang Y, et al. miR-99a promotes proliferation targeting FGFR3 in human epithelial ovarian cancer cells[J]. Biomedicine Pharmacotherapy, 2014, 68(2): 163-169.
[6] Farazi TA, Spitzer JI, Morozov P, et al. miRNAs in human cancer[J]. J Pathol, 2011, 223(2): 102-115.
[7] Bushati N, Cohen SM. microRNA functions[J]. Annu Rev Cell Dev Biol, 2007, 23:175-205.
[8] Calin GA, Croce CM. MicroRNA signatures in human cancers[J]. Nature reviews Cancer, 2006, 6(11): 857-866.
[9] 何玲, 林功标, 程金妹. MicroRNA在头颈肿瘤的研究进展[J]. 中华耳鼻咽喉头颈外科杂志, 2010, 2: 170-173.
[10] Tricoli JV, Jacobson JW. MicroRNA: Potential for Cancer Detection, Diagnosis, and Prognosis[J]. Cancer Res, 2007, 67(10): 4553-4555.
[11] Croce CM, Calin GA. miRNAs, cancer, and stem cell division[J]. Cell, 2005, 122(1): 6-7.
[12] Ahmed FE, Jeffries CD, Vos PW, et al. Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue[J]. Cancer Genomics Proteomics, 2009, 6(5): 281-295.
[13] Faruq O, Vecchione A. microRNA: Diagnostic Perspective[J]. Front Med, 2015, 2: 51. doi: 10.3389/fmed.2015.00051. eCollection 2015.
[14] Chen Z, Jin Y, Yu D, et al. Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma[J]. Oral Oncol, 2012, 48(8): 686-691.
[15] Li D, Liu X, Lin L, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma[J]. J Biol Chem, 2011, 286(42): 36677-36685.
[16] Sun D, Lee YS, Malhotra A, et al. miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation[J]. Cancer Res, 2011, 71(4): 1313-1324.
[17] Catto JW, Miah S, Owen HC, et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer[J]. Cancer Res, 2009, 69(21): 8472-8481.
[18] Torres A, Torres K, Pesci A, et al. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma[J]. BMC Cancer, 2012, 12: 369. doi: 10.1186/1471-2407-12-369
[19] Sun J, Chen Z, Tan X, et al. MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma[J]. Med Oncol, 2013, 30(1): 411. doi: 10.1007/s12032-012-0411-9. Epub 2013 Jan 5.
[20] Cui L, Zhou H, Zhao H, et al. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma[J]. BMC Cancer, 2012, 12: 546. doi: 10.1186/1471-2407-12-546.
[1] 栗英林,宋道庆,徐忠华. 应用生物信息学方法分析肾透明细胞癌中FKBP11的表达[J]. 山东大学学报 (医学版), 2020, 1(9): 45-51.
[2] 史爽,李娟,米琦,王允山,杜鲁涛,王传新. 胃癌miRNAs预后风险评分模型的构建与应用[J]. 山东大学学报 (医学版), 2020, 1(7): 47-52.
[3] 路璐,孙志钢,张楠. 继发性嗜血细胞综合征1例[J]. 山东大学学报 (医学版), 2020, 1(7): 122-124.
[4] 李星凯,刘战业,姜运峰,李军. 原发性中央型和周围型肺鳞癌临床病理学及预后差异[J]. 山东大学学报(医学版), 2017, 55(9): 73-78.
[5] 宗帅,肖东杰,刘华,郏雁飞,马晓丽,李焕杰,黎娉,郑燕,汪运山. CSN5在胃癌中的表达及与患者预后的相关性[J]. 山东大学学报(医学版), 2017, 55(7): 12-16.
[6] 孙启晶,陈方方,李春晓,张才擎. PNI及HGB评估中晚期非小细胞肺癌患者预后的临床价值[J]. 山东大学学报(医学版), 2017, 55(4): 55-59.
[7] 董尧,宋亚林,田涛,高建国. 确诊8年未经治疗却无明显进展的阴茎恶性黑色素瘤1例报道[J]. 山东大学学报(医学版), 2017, 55(3): 125-126.
[8] 林家香,郭子嘉,苏鹏,王晓,郭雅欣,吴晓娟,相磊,周志强, 王妍,崔秀杰,潘爱凤,郭成浩. 致癌蛋白CIP2A在乳腺导管上皮恶变中的作用及预测浸润性导管癌患者预后的能力[J]. 山东大学学报(医学版), 2017, 55(3): 100-106.
[9] 周兰兰,潘学谊,郭煜. 48例急性混合细胞表型白血病患者的临床特征及预后[J]. 山东大学学报(医学版), 2017, 55(2): 79-83.
[10] 张希英,翟春颜,李劲松,韩博. 中国尤文肉瘤患者EZH2蛋白表达与临床病理学参数及预后的关系[J]. 山东大学学报(医学版), 2017, 55(2): 84-91.
[11] 刘惠苓,王兴文,冯少滨,冯虹,韩俊庆. B类I型清道夫受体的高表达与结肠癌患者预后的相关性[J]. 山东大学学报(医学版), 2017, 55(10): 84-89.
[12] 李晓宁,崔连群. 急性心肌梗死合并多支血管病变患者非梗死相关动脉处理的时机[J]. 山东大学学报(医学版), 2016, 54(8): 50-54.
[13] 王雯,刘尧,龙飞,马卫霞,苏莉莉. 外周血淋巴细胞/单核细胞比值与恶性胸膜间皮瘤患者预后的关系[J]. 山东大学学报(医学版), 2016, 54(8): 72-77.
[14] 刘童,张欣,王传新. IRX5 mRNA在结直肠癌诊断及预后中的价值[J]. 山东大学学报(医学版), 2016, 54(7): 69-74.
[15] 马琳,张冬,唐蕾,叶嗣源,焉传祝,曹丽丽. 肌萎缩侧索硬化预后相关的血液学标志物[J]. 山东大学学报(医学版), 2016, 54(4): 46-50.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!